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Background: Gonadotropin releasing hormone (GNRH1) triggers the release of follicle
stimulating hormone and luteinizing hormone from the pituitary. Genetic variants in the gene
encoding GNRH1 or its receptor may influence breast cancer risk by modulating production of
ovarian steroid hormones. We studied the association between breast cancer risk and
polymorphisms in genes that code for GNRH1 and its receptor (GNRHR) in the large National
Cancer Institute Breast and Prostate Cancer Cohort Consortium (NCI-BPC3).
Methods: We sequenced exons of GNRH1 and GNRHR in 95 invasive breast cancer cases.
Resulting single nucleotide polymorphisms (SNPs) were genotyped and used to identify haplotype-
tagging SNPs (htSNPS) in a panel of 349 healthy women. The htSNPs were genotyped in 5,603
invasive breast cancer cases and 7,480 controls from the Cancer Prevention Study-II (CPS-II),
European Prospective Investigation on Cancer and Nutrition (EPIC), Multiethnic Cohort (MEC),
Nurses' Health Study (NHS), and Women's Health Study (WHS). Circulating levels of sex steroids
(androstenedione, estradiol, estrone and testosterone) were also measured in 4713 study subjects.
Results: Breast cancer risk was not associated with any polymorphism or haplotype in the GNRH1
and GNRHR genes, nor were there any statistically significant interactions with known breast cancer
risk factors. Polymorphisms in these two genes were not strongly associated with circulating
hormone levels.
Conclusion: Common variants of the GNRH1 and GNRHR genes are not associated with risk of
invasive breast cancer in Caucasians.
Background
Exposure to steroid hormones (estrogens and androgens)
is a risk factor for breast cancer. Increased exposure to
estrogens, for instance by early menarche, late meno-
pause, low parity and post-menopausal obesity, contrib-
utes to increased breast cancer risk (reviewed in ref. [1]).
High circulating levels of estrogens are associated with ele-
vated breast cancer risk [2,3].
The primary stimulus for production of estrogen and
other ovarian steroid hormones is the release of the gona-
dotropins, follicle-stimulating hormone (FSH) and lutei-
nizing hormone (LH), from the anterior pituitary. These
are released when gonadotropin-releasing hormone 1
(GNRH1), from the hypothalamus, binds to the gonado-
tropin-releasing hormone receptor (GNRHR) in the ante-
rior pituitary. The resultant G-protein activation of a
phosphatidylinositol-calcium second messenger system
ultimately triggers the release of FSH and LH.
GNRH1 activity is low during childhood but increases at
puberty. GNRH1 production is pulsatile. In females, the
GNRH1 pulse frequency varies during the menstrual
cycle, with a large surge of GNRH1 just before ovulation.
The size and frequency of the GNRH1 pulse, and feedback
from androgens and estrogens, control production of LH
and FSH [4].
GNRH1 activity can be disrupted by hypothalamic-pitui-
tary disease. Elevated prolactin levels decrease GNRH1
activity. In contrast, hyperinsulinemia increases pulse
activity leading to disorderly LH and FSH activity, as seen
in polycystic ovary syndrome [5].
The GNRH1 gene is located on chromosome 8p21.2. It
spans about 5 kb and contains 3 exons. It encodes the
GNRH1 precursor, which contains 92 amino acids and is
processed to GNRH1, a decapeptide. The GNRHR gene is
located on chromosome 4q13.2. Its genomic sequence
covers about 19 kb and it includes 3 exons.
The GNRH1 and GNRHR genes can harbor rare germline
mutations which lead to idiopathic hypogonadotropic
hypogonadism (IHH) or Kallmann syndrome (MIM
146110, 147950) in both men and women [6]. Common
variants have not been studied for either gene in relation
to cancer risk.
We hypothesized that common, functional polymor-
phisms of GNRH1 and GNRHR could influence breast
cancer risk by modifying production of FSH/LH and ster-
oid hormones. We used a haplotype tagging approach to




The BPC3 has been described in detail elsewhere [7].
Briefly, the consortium includes large, well-established
cohorts assembled in the United States and Europe, that
have both DNA samples and extensive questionnaire
information. These include: the American Cancer SocietyPage 2 of 8
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Prospective Investigation into Cancer and Nutrition
(EPIC) [9], the Harvard Nurse's Health Study (NHS) [10]
and Women's Health Study (WHS) [11], and the Multi-
ethnic Cohort (MEC) [12].
Cases were identified in each cohort by self report with
subsequent confirmation of the diagnosis from medical
records or tumor registries, and/or linkage with popula-
tion-based tumor registries (method of confirmation var-
ied by cohort). Controls were matched to cases by
ethnicity and age, and in some cohorts, additional criteria,
such as country of residence in EPIC.
Most of the subjects were Caucasians of European descent.
One cohort (MEC) provided most of the non-Caucasian
samples. In total, we genotyped 4,401 Caucasian cases
and 5,966 controls, 329 Latino cases and 385 controls,
341 African American cases and 426 controls, 425 Japa-
nese American cases and 418 controls, and 107 Native
Hawaiian cases and 285 controls.
Written informed consent was obtained from all subjects,
and the project has been approved by the competent insti-
tutional review boards for each cohort.
Selection of haplotype tagging single nucleotide 
polymorphisms (htSNPs)
We sequenced exons and intron/exon junctions of
GNRH1 and GNRHR in a panel of 95 metastatic breast
cancer cases from the MEC and EPIC. These included 19
cases from each ethnic group represented in the study
(African American, Latino, Japanese, Native Hawaiian,
and Caucasian). About 45 kb were surveyed for GNRH1
and about 56 kb for GNRHR. No non-synonymous or
splice-site variants were identified in sequencing of the
exons.
Based on the resequencing and SNPs available in dbSNP,
we identified 17 SNPs in GNRH1 and 36 SNPs in GNRHR
with minor allele frequency greater than 5% in any of the
five ethnic groups or greater than 1% overall. These SNPs
were genotyped in a reference panel of 349 healthy
women (70 African-Americans, 68 Latinos, 72 Japanese,
70 Caucasians, and 69 Hawaiians from the MEC cohort
who had not been diagnosed with breast cancer at the
time of the study; average age 65.1 (standard deviation
8.5)) at the Broad Institute (Cambridge, MA, USA) using
the Sequenom (San Diego, CA, USA) and Illumina (San
Diego, CA, USA) platforms.
Haplotype tagging SNPs (htSNPs) were then selected
using the method of Stram et al. [13] to maximize R2H
among Caucasians. Three htSNPs were selected for
GNRH1 (including one localized in the 5' neighboring
gene, KCTD9, and one in the gene at the 3', DOCK5) and
seven for GNRHR.
Genotyping
Genotyping of htSNPs was performed in 3 laboratories
(University of Southern California, Los Angeles, CA, USA;
Harvard School of Public Health, Boston, MA, USA; Inter-
national Agency for Research on Cancer, Lyon, France)
using a fluorescent 5' endonuclease assay and the ABI-
PRISM 7900 for sequence detection (TaqMan). Initial
quality control checks of the SNP assays were performed
by the manufacturer (Applied Biosystems, Foster City, CA,
USA); an additional 500 test reactions were run at the
University of Southern California. Characteristics for the
10 TaqMan assays are available on a public website http/
www.uscnorris.com/mecgenetics/CohortGCK View.aspx.
Sequence validation for each SNP assay was performed on
samples from the SNP500 project http://
snp500cancer.nci.nih.gov[14] and 100% concordance
was observed. To assess inter-laboratory variation, each
genotyping center ran assays on a designated set of 94
samples from the Coriell Biorepository (Camden, NJ,
USA) included in SNP500. The internal quality of geno-
type data at each genotyping center was assessed by typing
5–10% blinded samples in duplicate or triplicate
(depending on study).
Hormone Analysis
Circulating serum hormones were measured at the Inter-
national Agency for Research on Cancer for EPIC and
MEC samples and at the Harvard School of Public Health
for NHS samples, for a total of 4713 subjects (1405 cases
and 3308 controls, 1120 pre-menopausal and 3593 post-
menopausal subjects). The different assays for hormone
analyses were chosen on the basis of a previously pub-
lished comparative validation study [15]. Estradiol (E2),
estrone (E1) and androstenedione (Δ4) were measured by
direct double-antibody radioimmunoassays from DSL
(Diagnostic Systems Laboratories, Texas), while testoster-
one (T) was measured by direct radioimmunoassays from
Immunotech (Marseille, France). Measurements were per-
formed on never thawed serum sample aliquots. Mean
intrabatch and interbatch coefficients of variation were
5.8 and 13.1%, respectively, for E2 (at a concentration of
250 pmol/l), 10.2 and 12.6% for E1 (at 75 pmol/l), and
4.8 and 18.9% for Δ4 (at 1.40 nmol/l), 10.8 and 15.3% for
T (at 1.40 nmol/l).
Statistical Analysis
We used conditional multivariate logistic regression to
estimate odds ratios (ORs) for invasive breast cancer in
subjects with a linear (log-odds additive) scoring for 0, 1
or 2 copies of the minor allele of each SNP. We also used
conditional logistic regression with additive scoring and
the most common haplotype as the referent to estimatePage 3 of 8
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approach to assign haplotypes based on the unphased
genotype data and to account for uncertainty in assign-
ment [16,17]. Haplotype frequencies and expected sub-
ject-specific haplotype indicators were calculated
separately for each cohort (and country within EPIC or
ethnicity in the MEC). We combined rare haplotypes
(those with estimated individual frequencies less than 3%
in all cohorts) into a single category, which had a com-
bined frequency of less than 1% of the controls for both
genes and both linkage disequilibrium (LD) blocks of
GNRHR. To test the global null hypothesis of no associa-
tion between variation in GNRH1/GNRHR haplotypes
and htSNPs and risk of invasive breast cancer (or subtypes
defined by receptor status), we used a likelihood ratio test
comparing a model with additive effects for each com-
mon haplotype (treating the most common haplotype as
the referent) to the intercept-only model.
We performed subgroup analyses stratifying by cohort,
ethnicity, country within EPIC, estrogen receptor/proges-
terone receptor status, metastatic vs. localized disease, and
age at diagnosis (≤55 years vs. >55 years). We also investi-
gated interactions between single SNPs or haplotypes and
completion of a full term pregnancy (ever/never), age at
first full term pregnancy (in three categories: nulliparous,
≤24, >24), body mass index (BMI in kg/m2 in three cate-
gories: <25, 25–29, ≥30), height (<160 cm, 160–165 cm,
>165 cm), smoking status (never/former/current
smoker), and use of menopausal hormone therapy (ever/
never). Other common risk factors, including family his-
tory of breast cancer, personal history of benign breast dis-
ease, and age at menopause were unavailable for large
numbers of women, and therefore were not included in
the models.
Relationships of genetic variants with serum hormone lev-
els were estimated by standard regression models,
adjusted for BMI, age, assay batch, ethnicity, and country
within EPIC. These analyses were performed both using
all the study subjects for whom hormone levels have been
measured, and only the controls, who represent the pop-
ulations giving rise to the cases.
Results
The genomic regions surrounding GNRH1 and GNRHR
are shown in Figure 1. GNRH1 consists of a single LD
block, whereas GNRHR includes two LD blocks, one of
them including exon 1 and the other exons 2 and 3.
GNRH1 was tagged by 3 SNPs, which account for 94% of
haplotype diversity. Block 1 of GNRHR was tagged by 3
SNPs and block 2 by 4 SNPs (98% and 95% of haplotype
diversity, respectively). Frequency of common haplotypes
ranged between 19 and 35% in controls for GNRH1 and
5% and 52% for GNRHR.
A total of 5,603 invasive breast cancer cases and 7,480
controls were available for genotyping from each of the
participating cohorts. Samples not yielding a genotype
were removed from individual SNP analyses, and samples
not yielding at least one genotype were removed from
haplotype analyses. Both between-center genotyping con-
cordance and within-center blinded quality control con-
cordance were above 99%. Genotype success rate among
cases and controls in all cohorts was greater than 95%. No
polymorphisms deviated from Hardy-Weinberg Equilib-
rium among the controls.
Detailed results of associations between serum concentra-
tions of steroid hormones and SNPs are presented in
Additional file 1. SNP rs2630488 within GNRHR showed
a nominally significant association (p = 0.04) with estra-
diol levels in post-menopausal women. Presence of the
minor allele at this polymorphism was associated with an
increase in estradiol level (a 4% increase among homozy-
Haploview plot of the genomic region of GNRH1 (A) and GNRHR (B)Figure 1
Haploview plot of the genomic region of GNRH1 (A) 
and GNRHR (B). From top to bottom: position of genes 
(boxes: exons, lines: introns), SNPs genotyped in the multi-
ethnic panel, graphical representation of LD and block struc-
ture (darker color represents higher LD, numbers in the 
colored squares are percentage of LD, expressed as D', 
absence of number means D' = 100%).
A 
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for the common allele). However, this effect was entirely
driven by the association observed in post-menopausal
breast cancer cases within EPIC (p = 0.012 in this sub-
group), and was not observed in the other subgroups. A
few borderline associations were observed between hor-
mone levels and SNPs in pre-menopausal women, how-
ever sample size of this group of subjects was considerably
smaller, and all subjects derived from only one cohort
(EPIC). No associations between polymorphisms and
hormone levels remained significant after correction for
multiple testing.
Results of association analyses between htSNPs of GNRH1
and breast cancer risk are presented in Table 1, and results
of haplotype analysis in Table 2. Results of analyses for
GNRHR are presented in Tables 3 and 4. No association
was observed for any of the htSNPs of either gene. Haplo-
type analysis also showed no association, with global tests
for comparison of haplotypes frequency in cases and con-
trols resulting in non-significant results (Wald tests: d.f. =
4, p = 0.364 for GNRH1; d.f. = 5, p = 0.897 for GNRHR
block 1 and d.f. = 6, p = 0.967 for GNRHR block 2). Anal-
yses were unadjusted (conditional on matching criteria)
or adjusted for known breast cancer risk factors, but
results did not show any difference.
Analyses performed by stratifying cases by age at diagnosis
(greater or lower than 55 years), localized or metastatic
disease or estrogen/progesterone receptor status did not
show significant differences. Stratification of subjects by
cohort, country in EPIC or ethnicity in MEC showed only
few results supported by p values ranging from 0.01 to
0.05, which were always based on a small number of sub-
jects. For these, we performed heterogeneity tests, which
in all cases were not statistically significant. For example,
heterozygotes for SNP rs1812594 of GNRH1 had an odds
ratio (OR) of 1.08 (95% confidence interval (CI) = 1.00–
-1.16, p = 0.04). When we analyzed the results for each
cohort, it resulted that the association was driven by EPIC
data (OR = 1.16, 95% CI 1.00–1.34, p = 0.046), and
within EPIC the only significant result came from the
Spanish sub-cohort (OR = 1.59, 95% CI = 1.07–2.37, p =
0.021), which is based on 62 cases and 79 controls heter-
ozygous for this SNP. However, heterogeneity tests for this
genotype were not statistically significant for either the
entire study (p = 0.226) or within EPIC (p = 0.147). Nor
were homozygotes for the less common allele at this SNP
significantly associated with increased risk in any sub-
group.
No statistically significant interactions were observed
between htSNPs or haplotypes and known breast cancer
risk factors, including age at first full term pregnancy,
number of pregnancies, never/ever menopausal hormone
therapy, height, smoking status, or body mass index.
Discussion
This large, comprehensive study found no statistically sig-
nificant associations between polymorphisms in the
genes that code for GNRH1 or its receptor and either cir-
culating ovarian sex hormones or breast cancer risk. An
influence of SNPs in these two genes on breast cancer risk,
mediated by altered levels of estrogens, was plausible, due
to the known physiology of steroid hormone stimulation.
If any common variants with functional relevance exist in
the two candidate genes, our resequencing and haplotype
tagging approaches should have detected its effect on hor-
mone measurements and/or cancer risk. The null results
are especially convincing because of the large sample size
(more than 5,600 invasive breast cancer cases and 7,400
controls) and the extensive resequencing that preceded
and informed the selection of htSNPs. The study has over
80% power to detect main effects of common polymor-
phisms (minor allele frequency of 5% or greater) with rel-
ative risks of 1.2 or greater, and to investigate interactions
Table 1: Association between GNRH1 htSNPs and breast cancer risk in the BPC3 study.
SNP Genotype Cases (%) Controls (%) OR (95% CI)a p value
rs2709618 G/G 2,094 (38) 2,771 (38) 1.00 (ref.)
G/A 2,547 (46) 3,412 (46) 1.00 (0.93–1.08) 0.942
A/A 868 (16) 1,163 (16) 1.00 (0.90–1.10) 0.927
ptrend = 0.958
rs6185 C/C 3,023 (56) 4,036 (56) 1.00 (ref.)
C/G 1,963 (36) 2,684 (37) 0.98 (0.91–1.05) 0.597
G/G 418 (8) 545 (8) 0.99 (0.87–1.13) 0.889
ptrend = 0.695
rs1812594 T/T 3,424 (64) 4,565 (65) 1.00 (ref.)
T/C 1,730 (32) 2,158 (31) 1.08 (1.00–1.16) 0.040
C/C 203 (4) 285 (4) 0.98 (0.82–1.17) 0.825
ptrend = 0.156
aOdds ratios and 95% confidence intervals, calculated by unadjusted logistic regression analysis conditional on the matching variablesPage 5 of 8
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lifestyle exposures [18].
Based on these results, we conclude that common poly-
morphisms in GNRH1 and GNRHR do not substantially
affect breast cancer risk in Caucasians. Among the many
tests performed in subgroups, some associations were
supported by p values ranging from 0.01 and 0.05, yet
these associations were driven by subgroups containing
small numbers of cases, and are therefore compatible with
chance. None of these subgroup findings remain statisti-
cally significant when adjusted for multiple hypothesis
testing. Likewise, the weakly significant association we
observed between estradiol levels in post-menopausal
women and SNP rs2630488 of GNRHR derived from a
single subgroup in one cohort, and is also likely to reflect
chance.
A limitation of this study was the relatively small number
of subjects from racial or ethnic groups other than Cauca-
sian. The MEC provided most of the cases and controls in
this regard, but none of these groups exceeded 425 breast
cancer cases. This limitation is particularly relevant to Afri-
can Americans, for whom additional SNPs would be
needed to provide comparable coverage of common vari-
ants. Coverage is satisfactory for the other ethnic groups
[19]. This is consistent with genome-wide data [20],
which also showed that tagging SNPs for Caucasians offer
good coverage in other ethnic groups, except Africans.
Conclusion
In conclusion, we can exclude the possibility that com-
mon polymorphisms in GNRH1 and GNRHR confer large
or even moderate breast cancer risks in Caucasians. We
cannot exclude the possible existence of moderate risks
due to polymorphisms of GNRH1 and GNRHR in non-
Caucasian populations. Larger studies of non-Caucasians
will be necessary to test this hypothesis.
Table 2: Association between GNRH1 haplotypes and breast 
cancer risk in the BPC3 study.
Haplotype Cases (%) Controls (%) OR (95% CI)a p value
hGCT 2,024 (35) 2,697 (35) 1.00 (ref.)
hGGT 1,469 (26) 1,955 (26) 1.00 (0.94–1.06) 0.9480
hACC 1,137 (20) 1,487 (19) 1.04 (0.97–1.11) 0.2957
hACT 1,074 (19) 1,484 (19) 0.96 (0.90–1.03) 0.2240
Freq<3% 25 (<1) 34 (<1) 0.87 (0.58–1.31) 0.5056
aOdds ratios and 95% confidence intervals, calculated by unadjusted 
logistic regression analysis conditional on the matching variables
Table 3: Association between GNRHR htSNPs and breast cancer risk in the BPC3 study.
SNP Genotype Cases (%) Controls (%) OR (95% CI)a p value
rs13138607 G/G 1,413 (26) 1,948 (27) 1.00 (ref.)
G/A 2,696 (49) 3,550 (48) 1.03 (0.95–1.11) 0.484
A/A 1,380 (25) 1,829 (25) 1.01 (0.92–1.11) 0.789
ptrend = 0.781
rs4986942 G/G 4,650 (84) 6,200 (84) 1.00 (ref.)
G/A 867 (16) 1,136 (15) 1.04 (0.95–1.14) 0.350
A/A 34 (1) 41 (1) 0.99 (0.66–1.49) 0.967
ptrend = 0.402
rs10031252 T/T 1,503 (27) 2,093 (28) 1.00 (ref.)
T/A 2,694 (49) 3,566 (48) 1.02 (0.94–1.10) 0.640
A/A 1,324 (24) 1,701 (23) 1.02 (0.93–1.12) 0.641
ptrend = 0.637
rs3822196 A/A 3,259 (59) 4,202 (58) 1.00 (ref.)
A/G 1,872 (34) 2,589 (36) 0.96 (0.89–1.03) 0.223
G/G 350 (6) 480 (7) 0.97 (0.8–41.11) 0.622
ptrend = 0.273
rs3796718 T/T 2,951 (55) 3,868 (54) 1.00 (ref.)
T/C 2,053 (38) 2,761 (38) 0.98 (0.92–1.05) 0.642
C/C 409 (8) 571 (8) 0.96 (0.84–1.09) 0.497
ptrend = 0.461
rs1843593 T/T 4,012 (73) 5,277 (72) 1.00 (ref.)
T/C 1,357 (25) 1,843 (25) 1.01 (0.93–1.09) 0.831
C/C 122 (2) 188 (3) 0.98 (0.79–1.22) 0.848
ptrend = 0.942
rs2630488 A/A 1,530 (29) 1,959 (27) 1.00 (ref.)
A/G 2,618 (49) 3,489 (49) 1.00 (0.92–1.08) 0.942
G/G 1,200 (22) 1,694 (24) 0.96 (0.88–1.06) 0.436
ptrend = 0.458
aOdds ratios and 95% confidence intervals, calculated by unadjusted logistic regression analysis conditional on the matching variablesPage 6 of 8
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Table 4: Association between GNRHR haplotypes and breast 
cancer risk in the BPC3 study.
Haplotype Cases (%) Controls (%) OR (95% CI)a p value
Block 1
hAGA 2,426 (43) 3,161 (42) 1.00 (ref.)
hGGT 2,060 (36) 2,806 (37) 0.98 (0.93–1.03) 0.491
hGAT 473 (8) 620 (8) 1.02 (0.93–1.11) 0.712
hAGT 397 (7) 557 (7) 0.96 (0.87–1.06) 0.433
hGGA 307 (5) 400 (5) 0.97 (0.87–1.07) 0.522
Freq<3% 4 (<1) 6 (<1) 0.83 (0.31–2.25) 0.720
Block 2
hATTA 2,997 (53) 3,908 (52) 1.00 (ref.)
hGCTG 1,178 (21) 1,630 (22) 0.99 (0.92–1.06) 0.342
hATCG 667 (12) 937 (12) 1.00 (0.92–1.09) 0.731
hATTG 478 (8) 633 (8) 1.01 (0.89–1.14) 0.949
hACTG 177 (3) 214 (3) 0.98 (0.85–1.15) 0.862
hGCCG 150 (3) 206 (3) 1.11 (0.76–1.62) 0.836
Freq<3% 21 (<1) 22 (<1) 0.98 (0.93–1.03) 0.579
aOdds ratios and 95% confidence intervals, calculated by unadjusted 
logistic regression analysis conditional on the matching variablesPage 7 of 8
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